Human medicines European public assessment report (EPAR): Sylvant, siltuximab, Giant Lymph Node Hyperplasia, Date of authorisation: 22/05/2014, Revision: 8, Status: Authorised

2019 ◽  
Author(s):  
Sign in / Sign up

Export Citation Format

Share Document